The pathogenesis of Alzheimer's disease (AD) has been linked to the deficiency of neurotransmitter acetylcholine (ACh) in the brain, and the main treatment strategy for improving AD symptoms is the inhibition of acetylcholinesterase (AChE) activity. In the present study, we aimed to identify potent AChE inhibitors from Cinnamomum loureirii extract via bioassay-guided fractionation. We demonstrated that the most potent AChE inhibitor present in the C. loureirii extract was 2,4-bis(1,1-dimethylethyl)phenol. To confirm the antiamnesic effects of the ethanol extract of C. loureirii, mice were intraperitoneally injected with the neurotoxin trimethyltin (2.5 mg/kg) to induce cognitive dysfunction, and performance in the Y-maze and passive avoidance tests was assessed. Treatment with C. loureirii extract significantly improved performance in both behavioral tests, suggesting that this extract may be neuroprotective and therefore beneficial in preventing or ameliorating the degenerative processes of AD, potentially by restoring cholinergic function.
Key words Alzheimer's disease; Cinnamomum loureirii; acetylcholine; acetylcholinesterase inhibitorThe pathophysiology of Alzheimer's disease (AD), a type of dementia in the elderly, is highly complex. This progressive degenerative disorder was first discovered by Dr. Alois Alzheimer in 1907 and is characterized by incapacitating memory and language losses and impairments in cognitive and behavioral functions. A neuropathological diagnosis of AD includes deposition of extracellular β-amyloid (Aβ) plaques in the cerebral cortex and hippocampus areas, accumulation of intracellular neurofibrillary tangles of abnormally phosphorylated τ, astrocytic gliosis, inflammatory cascades, and degeneration of basal forebrain cholinergic neurons.